These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
809 related items for PubMed ID: 27866027
21. Sodium-glucose cotransporter 2 inhibitors: an evidence-based practice approach to their use in the natural history of type 2 diabetes. Schwartz SS, Ahmed I. Curr Med Res Opin; 2016 May; 32(5):907-19. PubMed ID: 26854518 [Abstract] [Full Text] [Related]
22. SGLT-2 inhibitors and the risk of infections: a systematic review and meta-analysis of randomized controlled trials. Puckrin R, Saltiel MP, Reynier P, Azoulay L, Yu OHY, Filion KB. Acta Diabetol; 2018 May; 55(5):503-514. PubMed ID: 29484489 [Abstract] [Full Text] [Related]
27. The effect of sodium-glucose cotransporter 2 inhibitors in patients with chronic kidney disease with or without type 2 diabetes mellitus on cardiovascular and renal outcomes: A systematic review and meta-analysis. Reyes-Farias CI, Reategui-Diaz M, Romani-Romani F, Prokop L. PLoS One; 2023 May; 18(11):e0295059. PubMed ID: 38019892 [Abstract] [Full Text] [Related]
28. SGLT-2 Inhibitors and Cardiovascular Risk in Diabetes Mellitus: A Comprehensive and Critical Review of the Literature. Imprialos K, Faselis C, Boutari C, Stavropoulos K, Athyros V, Karagiannis A, Doumas M. Curr Pharm Des; 2017 May; 23(10):1510-1521. PubMed ID: 28120716 [Abstract] [Full Text] [Related]
30. Effects of SGLT2 inhibitors on cardiovascular outcomes and mortality in type 2 diabetes: A meta-analysis. Zou CY, Liu XK, Sang YQ, Wang B, Liang J. Medicine (Baltimore); 2019 Dec; 98(49):e18245. PubMed ID: 31804352 [Abstract] [Full Text] [Related]
31. Cardiovascular outcomes with sodium-glucose cotransporter-2 inhibitors vs other glucose-lowering drugs in 13 countries across three continents: analysis of CVD-REAL data. Khunti K, Kosiborod M, Kim DJ, Kohsaka S, Lam CSP, Goh SY, Chiang CE, Shaw JE, Cavender MA, Tangri N, Franch-Nadal J, Holl RW, Jørgensen ME, Norhammar A, Eriksson JG, Zaccardi F, Karasik A, Magliano DJ, Thuresson M, Chen H, Wittbrodt E, Bodegård J, Surmont F, Fenici P, CVD-REAL Investigators and Study Group. Cardiovasc Diabetol; 2021 Jul 31; 20(1):159. PubMed ID: 34332558 [Abstract] [Full Text] [Related]
35. Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular disease, death and safety outcomes in type 2 diabetes - A systematic review. Rådholm K, Wu JH, Wong MG, Foote C, Fulcher G, Mahaffey KW, Perkovic V, Neal B. Diabetes Res Clin Pract; 2018 Jun 31; 140():118-128. PubMed ID: 29604389 [Abstract] [Full Text] [Related]
39. Effects of glucose-lowering and multifactorial interventions on cardiovascular and mortality outcomes: a meta-analysis of randomized control trials. Seidu S, Achana FA, Gray LJ, Davies MJ, Khunti K. Diabet Med; 2016 Mar 31; 33(3):280-9. PubMed ID: 26282461 [Abstract] [Full Text] [Related]
40. Effects of SGLT-2 inhibitors on diabetic ketoacidosis: A meta-analysis of randomised controlled trials. Monami M, Nreu B, Zannoni S, Lualdi C, Mannucci E. Diabetes Res Clin Pract; 2017 Aug 31; 130():53-60. PubMed ID: 28570924 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]